Study identifies novel function of SMS enzyme to facilitate colorectal cancer growth

A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase (SMS) to facilitate colorectal cancer growth.

SMS is an enzyme that produces spermine from spermidine, which has been shown to be important for cell growth. However, excessive accumulation of spermidine can have harmful effects on cell viability. How cancer cells maintain a relatively high level of spermidine but below the toxic threshold to facilitate tumor growth is not well understood.

A group led by the Markey Cancer Center researcher Qing-Bai She, a professor in the UK College of Medicine's Department of Pharmacology and Nutritional Sciences, discovered that SMS is overexpressed in colorectal cancers and plays an important role in balancing cellular spermidine levels that are a necessary adaptation for colorectal cancer growth.

The group further revealed a link between the signaling of SMS and the oncogene MYC, a gene that plays a role in many cancer types, to maintain colorectal cancer cell survival. The study showed that combined inhibition of SMS and MYC signaling induced cancer cell death and tumor regression, which could be a promising strategy for colorectal cancer therapy.

Our findings provide an in-depth understanding of how the polyamine metabolic pathway interacts with oncogenic signaling pathways in tumorigenesis and highlight the unmet need of clinically effective SMS inhibitors for the targeted therapy."

Qing-Bai She, Professor, UK College of Medicine's Department of Pharmacology and Nutritional Sciences

The findings were published on June 26, 2020 in Nature Communications.

Source:
Journal reference:

Guo, Y., et al. (2020) Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim expression. Nature Communications. doi.org/10.1038/s41467-020-17067-x.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New radiopharmaceutical shows therapeutic efficacy in preclinical model of ovarian cancer